| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ... Blood 109 (2), 399-404, 2007 | 464 | 2007 |
| Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells X Zhu, M Badawi, S Pomeroy, DS Sutaria, Z Xie, A Baek, J Jiang, ... Journal of extracellular vesicles 6 (1), 1324730, 2017 | 449 | 2017 |
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ... Journal of clinical oncology 29 (17), 2357, 2011 | 352 | 2011 |
| Discovery and mechanism of highly efficient cyclic cell-penetrating peptides Z Qian, A Martyna, RL Hard, J Wang, G Appiah-Kubi, C Coss, MA Phelps, ... Biochemistry 55 (18), 2601-2612, 2016 | 299 | 2016 |
| miR-221 silencing blocks hepatocellular carcinoma and promotes survival JK Park, T Kogure, GJ Nuovo, J Jiang, L He, JH Kim, MA Phelps, ... Cancer research 71 (24), 7608-7616, 2011 | 290 | 2011 |
| Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease TS Lin, AS Ruppert, AJ Johnson, B Fischer, NA Heerema, LA Andritsos, ... Journal of Clinical Oncology 27 (35), 6012, 2009 | 290 | 2009 |
| Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry Z Wu, W Gao, MA Phelps, D Wu, DD Miller, JT Dalton Analytical chemistry 76 (3), 839-847, 2004 | 255 | 2004 |
| Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats W Gao, PJ Reiser, CC Coss, MA Phelps, JD Kearbey, DD Miller, ... Endocrinology 146 (11), 4887-4897, 2005 | 234 | 2005 |
| Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia MA Phelps, TS Lin, AJ Johnson, E Hurh, DM Rozewski, KL Farley, D Wu, ... Blood, The Journal of the American Society of Hematology 113 (12), 2637-2645, 2009 | 207 | 2009 |
| Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others JP Kitzmiller, DK Groen, MA Phelps, W Sadee Cleveland Clinic journal of medicine 78 (4), 243, 2011 | 185 | 2011 |
| The extracellular RNA communication consortium: establishing foundational knowledge and technologies for extracellular RNA research S Das, AB Abdel-Mageed, C Adamidi, PD Adelson, KM Akat, E Alsop, ... Cell 177 (2), 231-242, 2019 | 181 | 2019 |
| REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer C Comins, J Spicer, A Protheroe, V Roulstone, K Twigger, CM White, ... Clinical cancer research 16 (22), 5564-5572, 2010 | 152 | 2010 |
| Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study R Molokie, D Lavelle, M Gowhari, M Pacini, L Krauz, J Hassan, V Ibanez, ... PLoS medicine 14 (9), e1002382, 2017 | 135 | 2017 |
| Achieving the promise of therapeutic extracellular vesicles: the devil is in details of therapeutic loading DS Sutaria, M Badawi, MA Phelps, TD Schmittgen Pharmaceutical research 34, 1053-1066, 2017 | 123 | 2017 |
| Discovery of anticancer agents of diverse natural origin AD Kinghorn, EJC De Blanco, DM Lucas, HL Rakotondraibe, J Orjala, ... Anticancer research 36 (11), 5623-5637, 2016 | 123 | 2016 |
| Dose escalation of lenalidomide in relapsed or refractory acute leukemias W Blum, RB Klisovic, H Becker, X Yang, DM Rozewski, MA Phelps, ... Journal of Clinical Oncology 28 (33), 4919-4925, 2010 | 117 | 2010 |
| Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines MA Bill, C Nicholas, TA Mace, JP Etter, C Li, EB Schwartz, JR Fuchs, ... Public Library of Science 7 (8), e40724, 2012 | 100 | 2012 |
| Modeling of active transport systems EY Zhang, MA Phelps, C Cheng, S Ekins, PW Swaan Advanced Drug Delivery Reviews 54 (3), 329-354, 2002 | 99 | 2002 |
| PRMT5 as a druggable target for glioblastoma therapy YK Banasavadi-Siddegowda, AM Welker, M An, X Yang, W Zhou, G Shi, ... Neuro-oncology 20 (6), 753-763, 2018 | 94 | 2018 |
| Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide–CCI-779 interaction via P-glycoprotein CC Hofmeister, X Yang, F Pichiorri, P Chen, DM Rozewski, AJ Johnson, ... Journal of clinical oncology 29 (25), 3427, 2011 | 87 | 2011 |
john C. ByrdDistinguished University Professor, The Ohio State University在 osumc.edu 的电子邮件经过验证
